Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 10326
Country/Region: Uganda
Year: 2015
Main Partner: University Research Corporation, LLC
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: USAID
Total Funding: $8,064,028 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $2,671,466
Care: TB/HIV (HVTB) $290,933
Care: Pediatric Care and Support (PDCS) $545,498
Laboratory Infrastructure (HLAB) $200,000
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $449,611
Testing: HIV Testing and Counseling (HVCT) $387,757
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $375,135
Treatment: Adult Treatment (HTXS) $2,937,644
Treatment: Pediatric Treatment (PDTX) $205,984
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 23,501
CARE_CURR_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 2,387
CARE_CURR_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 45,883
CARE_CURR_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 2,835
CARE_CURR_DSD Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 74,606
CARE_CURR_DSD Sum of Aggregated Age/Sex disaggregates 2016 74,606
CARE_NEW_DSD Aggregated Age/sex: <15 Female 2016 335
CARE_NEW_DSD Aggregated Age/sex: <15 Male 2016 296
CARE_NEW_DSD Aggregated Age/sex: 15+ Female 2016 5,782
CARE_NEW_DSD Aggregated Age/sex: 15+ Male 2016 3,145
CARE_NEW_DSD Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 9,558
CARE_NEW_DSD Sum of Aggregated Age/sex disaggregates 2016 9,558
CARE_NEW_TA Sum of Aggregated Age/sex disaggregates 2016 9,558
FN_THER_DSD Aggregated Age: <18 2016 689
FN_THER_DSD Aggregated Age: 18+ 2016 1,102
FN_THER_DSD Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period 2016 1,791
FN_THER_DSD Number of PLHIV who were nutritionally assessed and found to be clinically undernourished 2016 22,382
FN_THER_DSD Sum of Aggregated Age disaggregates 2016 1,791
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 17,469
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 13,178
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 133,231
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 96,041
HTC_TST_DSD By Test Result: Negative 2016 250,851
HTC_TST_DSD By Test Result: Positive 2016 9,068
HTC_TST_DSD Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 259,919
HTC_TST_DSD Sum of Aggregated Age/Sex <15 2016 30,647
HTC_TST_DSD Sum of Aggregated Age/Sex 15+ 2016 229,272
HTC_TST_DSD Sum of Aggregated Age/Sex disaggregates 2016 259,919
HTC_TST_DSD Sum of Test Result disaggregates 2016 259,919
LAB_CAP_DSD Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2016 18
PMTCT_ARV_DSD Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 4,068
PMTCT_ARV_DSD Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 4,068
PMTCT_ARV_DSD Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 3,450
PMTCT_ARV_DSD Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 618
PMTCT_ARV_DSD Sum of New and Current disaggregates 2016 4,068
PMTCT_EID_DSD By infants who received their first virologic HIV test between 2 and 12 months of age 2016 325
PMTCT_EID_DSD Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 3,256
PMTCT_EID_DSD Sum of Infant Age disaggregates 2016 3,253
PMTCT_STAT_DSD By: Known positives at entry 2016 3,450
PMTCT_STAT_DSD By: Number of new positives identified 2016 618
PMTCT_STAT_DSD Number of new ANC and L&D clients 2016 57,520
PMTCT_STAT_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 54,643
PMTCT_STAT_DSD Sum of Positives Status disaggregates 2016 4,068
PP_PREV_TA Age/sex: 10-14 Female 2016 6,974
PP_PREV_TA Age/sex: 10-14 Male 2016 5,343
PP_PREV_TA Age/sex: 15-19 Female 2016 17,271
PP_PREV_TA Age/sex: 15-19 Male 2016 10,879
PP_PREV_TA Age/sex: 20-24 Female 2016 26,110
PP_PREV_TA Age/sex: 20-24 Male 2016 12,488
PP_PREV_TA Age/sex: 25-49 Female 2016 36,847
PP_PREV_TA Age/sex: 25-49 Male 2016 20,824
PP_PREV_TA Age/sex: 50+ Female 2016 1,852
PP_PREV_TA Age/sex: 50+ Male 2016 1,689
PP_PREV_TA Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2016 140,277
PP_PREV_TA Sum of Age/Sex disaggregates 2016 140,277
TB_ART_DSD Aggregated Age: <15 2016 75
TB_ART_DSD Aggregated Age: 15+ 2016 995
TB_ART_DSD Female 2016 690
TB_ART_DSD Male 2016 380
TB_ART_DSD Sum of Aggregated Age disaggregates 2016 1,070
TB_ART_DSD Sum of Sex disaggregates 2016 1,070
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2016 1,070
TB_SCREEN_DSD Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 2016 5,222
TB_SCREEN_DSD Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ 2016 69,384
TB_SCREEN_DSD Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 74,606
TB_SCREEN_DSD Sex: Female 2016 48,718
TB_SCREEN_DSD Sex: Male 2016 25,888
TB_SCREEN_DSD Sum of Aggregated Age disaggregates 2016 74,606
TB_SCREEN_DSD Sum of Sex disaggregates 2016 74,606
TB_SCREEN_DSD The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2016 74,606
TX_CURR_DSD Aggregated Age/Sex: 15+ Female 2016 20,334
TX_CURR_DSD Aggregated Age/Sex: 15+ Male 2016 44,179
TX_CURR_DSD Number of adults and children receiving antiretroviral therapy (ART) 2016 69,639
TX_CURR_DSD Sum of Aggregated Age/Sex 15+ 2016 64,513
TX_CURR_DSD Sum of Aggregated Age/Sex disaggregates 2016 64,513
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Female 2016 4,766
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Male 2016 10,068
TX_NEW_DSD Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 15,476
TX_NEW_DSD Sum of Aggregated Age/Sex disaggregates 2016 14,834
TX_RET_DSD Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2016 11,028
TX_RET_DSD Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2016 12,974
VMMC_AE_DSD Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs) 2016 43
VMMC_CIRC_DSD By circumcision technique: Device-based VMMC 2016 1,288
VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 2016 11,593
VMMC_CIRC_DSD By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2016 11,593
VMMC_CIRC_DSD By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site 2016 2,834
VMMC_CIRC_DSD By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2016 9,815
VMMC_CIRC_DSD By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) 2016 232
VMMC_CIRC_DSD Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2016 12,881
Cross Cutting Budget Categories and Known Amounts Total: $635,000
Human Resources for Health $335,000
Key Populations: MSM and TG $100,000
Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Training of health workers and community outreach workers
Collection and use of strategic information
Monitoring and evaluation of MSM/TG programs
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW $200,000
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Collection and use of strategic information on SWs and clients
Training of health workers and community outreach workers
Monitoring and evaluation of SW programs
Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs